This week, Oklahoma legislature gave final approval for House Bill 2154, which excludes cannabidiol (CBD) from the state’s controlled substances act.
This bill states that physicians may recommend liquid preparations containing CBD and no more than three-tenths of one percent THC to patients with pediatric epilepsy. The measure also encourages clinical trials assessing the use of CBD in adolescent subjects. The measure provides no in state source for CBD oils and stipulates that such products must be derived from either the “seeds” or “mature stalks” of the marijuana plant. The bill now awaits action from the Governor, who has expressed support for the legislation.
NORML, an advocacy group for the responsible use of marijuana, reports that in 2014, eleven states enacted similar legislation; though as of yet none of these measures have been implemented in a manner that sufficiently provides patient access to these therapies. Madison, Wisconsin is just one of the many cities and states across the country that have seen stalled progress after these progressive bills were passed.